Trial Condition(s):
Endometriosis
To evaluate effectiveness of Visanne in improving quality of life in asian women with Endometriosis (ENVISIOeN)
Bayer Identifier:
17444
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
This study is a prospective observational cohort study. The study will be conducted in routine clinical practice settings. It is planned to enroll 870 patients with endometriosis for whom a decision has been made by the physician to treat with dienogest according to local health authority approved label. It is the aim of this observational cohort study to further characterize the effectiveness of dienogest in improving quality of life and long-term safety in routine clinical practice setting. Endometriosis is chronic and progressive disease and there is unmet need for long-term treatment. Visanne® with proven efficacy and safety, can be good option for long-term treatment, however, experience with Visanne® beyond 15 month is limited. And long-term up to 24 months data on effectiveness and safety of Visanne would support the long-term treatment strategy for Endometriosis management in the clinical practice.
Inclusion Criteria
- Asian Female patients at least 18 years of age - Clinical or surgical diagnosis of endometriosis (depending on local approved indication) : Clinical diagnosis by suggestive symptoms and positive finding in imaging study (Chocolate cyst) - Patients with Endometriosis associated pelvic pain - Decision taken by the physician to newly prescribe Visanne® - Availability of a signed informed consent
Exclusion Criteria
- Patients participating in an investigational program with interventions outside of routine clinical practice - Patients for whom any of contraindication listed in the local summary of product characteristics (SPC) apply.
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Investigative Site Many Loactions, Indonesia | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Loactions, South Korea | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Loactions, Malaysia | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Loactions, Philippines | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Loactions, Thailand | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Loactions, Singapore | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
EffectiveNess of VISanne® in improving quality of life in asIan wOmen with eNdometriosis
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- The mean change from baseline to 6 months of treatment in pain-related Quality of Life measured by EHP-30.Timeframe: Baseline and at 6 months
- The mean change from baseline to 24 months of treatment in pain-related Quality of Life measured by EHP-30 for patients who continue to take Visanne up to 24 months.Timeframe: Baseline and to 24 months
Secondary Outcome
- Mean change from baseline to 6 months and baseline to 24 months of treatment in other domain of Quality of life measured by EHP-30Other domain includes control and powerlessness, emotional wellbeing, social support, self-image as well as modular domain including work life, sexual intercourse, relationship with children, treatment and concern on infertilityTimeframe: Baseline and 6 months,Baseline to 24 months
- Mean change of Endometriosis-associated pelvic pain (EAPP) from baseline in patients with endometriosis either surgically or clinically diagnosed.Timeframe: Baseline and 6 months, Baseline and 12 months, Baseline and 24 months
- Patient and physician’s satisfaction score on Visanne® treatmentThe subject and physician will be asked to choose any of following; very satisfied, somewhat satisfied, neither satisfied or dissatisfied, somewhat dissatisfied, very dissatisfied.Timeframe: At 6 months, 12 months, 24 months
- Proportion of subjects who continue treatment with Visanne®Timeframe: At 6 months, 12 months, 24 months
- Reasons for stopping of treatment with Visanne®Timeframe: At 6 months, 12 months, 24 months
- Proportion of patients with amenorrhea, intermenstrual bleeding/spotting or irregular bleeding while treatment with Visanne®Timeframe: At 1 month, 3 months, 6 months, 12 months, and 24 months
- Proportion of patients who experienced pain recurrence in patients taking Visanne up to 24 monthsTimeframe: Up to 24 months
- Time point for first pain recurrence after stopping taking Visanne and before to start any treatment.Pain recurrence is defined as severity of pain graded > 4 on the 10-point NRSTimeframe: Up to 24 months
- Proportion of patients who underwent repeated surgery in patients taking Visanne up to 24 monthsTimeframe: Up to 24 months
- Proportion of patients who underwent repeated surgery between stopping Visanne treatment and starting any other treatment than surgeryTimeframe: Up to 24 months
- Patient’s assessment of overall symptom development using the Clinical Global Impression (CGI) scaleTimeframe: At 6 months, 12 months, 24 months
Additional Information
Copyright © Bayer
Powered by
